Research programme: TRPV1 receptor agonists - Medifron

Drug Profile

Research programme: TRPV1 receptor agonists - Medifron

Alternative Names: MDR-652

Latest Information Update: 31 Jul 2016

Price : $50

At a glance

  • Originator Digital Biotech
  • Developer Medifron DBT
  • Class Analgesics
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies; Postherpetic neuralgia

Most Recent Events

  • 31 Jul 2016 Preclinical trials in Diabetic neuropathies in South Korea (Transdermal)
  • 31 Jul 2016 Preclinical trials in Postherpetic neuralgia in South Korea (Transdermal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in South Korea (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top